RheaVita Corporation RheaLyo Mono System

In the manufacturing of biopharmaceuticals, freeze-drying is a crucial process that affects the stability, quality, and preservation of the product. In traditional batch freeze-drying, there can be challenges related to processing time, scale-up transitions, and monitoring conditions during the process. In this seminar, we will invite Dr. Thomas De Beer from RheaVita to give a presentation on continuous and controlled freeze-drying processes utilizing spin freeze-drying, PAT, and closed-loop control. June 23 (Tuesday) 16:30~

From March 24 (Tuesday) to March 27 (Friday), 2026, RheaVita will exhibit as a conference sponsor at ISLFD, held in Fukuoka, in collaboration with Lifix Analytical. ISLFD is an international conference where researchers and engineers involved in freeze-drying and related technologies gather from around the world to exchange information and discuss research results and technological trends. Through our sponsorship at this conference, RheaVita will present the latest information on spin freeze-drying technology. At our booth, in addition to introducing the latest information about spin freeze-dryers, we will be open to consultations on a wide range of topics, including research and development, feasibility testing, scaling up, and comparisons with existing processes. We aim to create a valuable platform for information exchange for those asking questions such as "What is spin freeze-drying?", "What are the differences from conventional freeze-drying processes?", "What are the challenges of scaling up and reproducibility?", and "What new formulation and manufacturing approaches should be considered?". Additionally, individual meetings will be possible during the conference. If you contact us in advance, we will secure a meeting opportunity at a time that is convenient for you. Please be sure to stop by the RheaVita booth.

Award to RheaVita by Pharma Tech Outlook This award is backed by numerous recommendations from many readers of Pharma Tech Outlook and is a testament to the strong trust and high evaluation RheaVita has received from customers and industry stakeholders. As a result of a rigorous review by top executives, industry experts, and the editorial board, RheaVita has been selected as the "Top Pharmaceutical Freeze Drying Solution in Europe 2025."

In recent years, the pharmaceutical industry has rapidly advanced the development of biopharmaceuticals such as therapeutic proteins and vaccines. These drugs face challenges regarding stability in aqueous solution, which is why freeze-drying has become an essential technology for long-term storage. Traditional freeze-drying is conducted in a batch process that handles multiple vials at once, resulting in long processing times and high costs. Furthermore, controlling the freezing process is difficult, leading to variations in ice crystal size among vials, which causes inconsistencies in drying rates and poses challenges for ensuring product quality uniformity. Additionally, the heat distribution within the drying chamber is uneven, raising concerns about the risk of product collapse and quality variability. To address these issues, a new manufacturing technology called "continuous freeze-drying" has emerged in recent years. This technology combines continuous supply of raw materials with continuous discharge of products, achieving shorter processing times, cost reductions, and smaller equipment. Moreover, it reduces quality differences between vials, allowing for the efficient production of uniform and stable products. This groundbreaking technology has been further commercialized by RheaVita since its introduction in 2019, and in March 2025, a GMP-compliant system was implemented at their headquarters in Belgium.